Recent developments include the Q2 2026 earnings release reporting a net loss but strong revenue, the acquisition of Proteintech Genomics to expand proteomics capabilities, and ongoing business activities covered in multiple news articles.

• 10x Genomics reported a net loss of $17.9 million for Q2 2026, with revenue of $151 million, driven by strong consumables sales despite a decline in instruments revenue [N1][N2].
• The company completed the acquisition of Proteintech Genomics, Inc. in June 2026, enhancing its multiomics and proteomics capabilities [N6].
• Recent news coverage highlights the company’s earnings performance and strategic business developments in the life sciences sector [N1][N2][N3][N6].

The company’s integrated solutions for single cell and spatial biology address complex research needs with proprietary technology and bundled software, supporting customer workflow efficiency. Expansion into proteomics through acquisitions like Proteintech Genomics broadens its product capabilities. Strong liquidity and global customer base provide a foundation for continued investment in innovation and market penetration.

The company has a history of operating losses and an accumulated deficit exceeding $1.5 billion, reflecting ongoing investment and potential challenges in achieving profitability. Revenue from instruments has declined in recent periods, and the business depends on continued adoption of its technology in a competitive market. Contingent consideration payments and acquisition-related expenses may impact financial flexibility. Market and regulatory risks inherent in life sciences technology could affect business performance.

10x Genomics' moat is built on its integrated product ecosystem combining proprietary instruments, consumables, and software tailored for complex biological analysis at single cell and spatial resolution. Its proprietary microfluidic chips and reagents, combined with bundled software, create high switching costs for customers. The company's ongoing investments in research and development and strategic acquisitions, such as Proteintech Genomics, support technological leadership and expansion into multiomics capabilities, reinforcing its competitive position in the life sciences research tools market.

• Operating Losses and Profitability: The company has generated losses since inception and reported a net loss of $17.9 million for Q2 2026, with an accumulated deficit of approximately $1.5 billion, indicating ongoing challenges in achieving sustained profitability.
• Market Competition and Adoption: The life sciences research tools market is competitive, and the company’s revenue from instruments declined in recent periods, which may reflect challenges in market adoption or competitive pressures.
• Acquisition and Integration Risks: Recent acquisitions, including Proteintech Genomics and Scale Biosciences, involve contingent consideration and integration risks that could affect financial results and operational focus.
• Liquidity and Capital Requirements: While liquidity ratios are strong as of June 30, 2026, future capital needs depend on revenue growth, R&D investments, acquisitions, and market conditions, which may require additional funding sources.

• 10x Genomics, Inc. is a life sciences technology company focused on building innovative products and solutions to interrogate, understand, and master biology [S1].
• The company offers integrated research solutions including instruments, consumables, and software for analyzing biological systems at resolution and scale matching biological complexity [S1].
• Its commercial product portfolio includes Single Cell and Spatial solutions, with instruments such as Chromium instruments, Visium CytAssist, and Xenium Analyzer, and consumables including proprietary microfluidic chips, slides, reagents, and other consumables [S1].
• Software is bundled with products to guide customers through workflows from sample preparation to analysis and visualization [S1].
• Customers purchase instruments and consumables for use in experiments and also derive revenue from post-warranty service contracts [S1].
• The company operates as a single operating and reportable segment, managed on a consolidated basis by the CEO [S1].
• Revenue is generated from product sales (instruments and consumables) and services, recognized generally upon shipment or order, with extended warranty revenue recognized ratably over the warranty period [S1].
• Contracts with customers often include combinations of products and services accounted for as separate performance obligations, with transaction prices allocated based on standalone selling prices [S1].
• On June 8, 2026, 10x Genomics acquired Proteintech Genomics, Inc. for $6.1 million in cash, a division specializing in high-plex proteomic solutions for single cell and spatial applications on 10x platforms, expanding the company's proteomics capabilities [S2].
• Concurrently, a supply agreement with Proteintech was entered, with $12.4 million allocated to the supply agreement and $6.1 million to the business acquisition, with the supply agreement assets reclassified to inventory over a 10-year period [S2].
• For the quarter ended June 30, 2026, the company reported a net loss of $17.9 million and basic and diluted EPS of -$0.14 [S2].
• As of June 30, 2026, 10x Genomics had cash and equivalents of approximately $344 million and a current ratio of 5.69, indicating strong liquidity [S2].
• Revenue for the three months ended June 30, 2026 was $151 million, with products and services revenue of $149 million and license and royalty revenue of $1.9 million [S2].
• Revenue by product category for Q2 2026 included instruments revenue of $7.7 million (down from $14.5 million in Q2 2025) and consumables revenue of $130.8 million (up from $122.2 million in Q2 2025) [S2].
• Geographically, the majority of revenue comes from the Americas, with $85 million in Q2 2026, followed by Europe, Middle East and Africa with $40 million, and Asia-Pacific with $26 million [S2].
• The company has made milestone payments related to acquisitions, including $10 million in cash and $8.7 million in shares in Q1 2026 for a technology transfer related to Scale Biosciences acquisition, with potential future contingent payments up to $30 million [S2].
• Operating expenses for Q2 2026 included research and development expenses of $56.8 million and selling, general and administrative expenses of $78.7 million [S2].
• The company has generated losses from operations since inception, with an accumulated deficit of approximately $1.5 billion as of June 30, 2026 [S2].
• 10x Genomics has a history of acquisitions and investments to expand its technology and market reach, including Scale Biosciences and Proteintech Genomics [S2].
• The company bundles software with its hardware and consumables to provide integrated solutions for single cell and spatial biology research [S1].
• The company’s revenue recognition policies reflect standard industry practices, with revenue recognized upon transfer of control and ratable recognition for extended warranties [S1].
• The company’s liquidity position as of June 30, 2026 includes $344 million in cash and equivalents, current assets of $675 million, current liabilities of $119 million, resulting in a cash ratio of 2.9 and current ratio of 5.69 [S2].
• The company’s stockholders’ equity was approximately $826 million as of June 30, 2026, with accumulated deficit of $1.54 billion [S2].
• The company’s product revenue is split between instruments and consumables, with consumables representing the larger portion of revenue [S2].
• The company’s customer base is global, with significant revenue from the United States, Europe, and Asia-Pacific regions [S2].
• The company’s recent news coverage includes reports on Q2 2026 earnings, acquisition of Proteintech Genomics, and expansion of multiomics capabilities [N1][N2][N6].